Premium
Reduced Cholecystokinin Levels in Cerebrospinal Fluid of Parkinsonian and Schizophrenic Patients Effect of Ceruletide in Schizophrenia a
Author(s) -
LOTSTRA F.,
VERBANCK P. M. P.,
GILLES C.,
MENDLEWICZ J.,
VANDERHAEGHEN JJ.
Publication year - 1985
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.1985.tb29944.x
Subject(s) - neuropathology , queen (butterfly) , medicine , psychiatry , disease , hymenoptera , botany , biology
The preliminary double-blind cross-over study does not indicate that ceruletide exerts antipsychotic action on schizophrenic patients free from neuroleptics. Because schizophrenia is an heterogenous disorder, a differential response to ceruletide in certain subtypes (particularly in acute cases) cannot be excluded at the present stage. A reduction of CCK levels is reported in the CSF of parkinsonian and schizophrenic patients free of neuroleptics. A double-blind cross-over study does not show that ceruletide has antipsychotic properties in neuroleptic-free patients suffering from schizophrenia.Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tSCOPUS: NotDefined.jFLWNAinfo:eu-repo/semantics/publishedNeuronal Cholecystokini